Developed by GlaxoSmithKline (GSK), Cervarix obtained marketing authorization last year. Cervical cancer protective vaccines are revolutionizing women’s health. Damage to the cervix is the second leading cause of cancer death in women.
Like Gardasil, Cervarix is reimbursed at 65% by Social Security. The reimbursement applies to all 14-year-old girls and young women aged 15 to 23, who have not yet had sex.
It is a little cheaper than its competitor Gardasil, at 111.82 euros per dose. Vaccination against cervical cancer requires three injections: at D0, then a month later and six months later.
In France, 3,400 new cases of cervical cancer and 1,000 deaths are reported each year.
